Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

Ophthalmology

Volumn 106, Issue 5, 1999, Pages 1024-1029

  Moroi, Sayoko E ^a   Gottfredsdottir, Maria S ^a   Schteingart, Miriam T ^b   Einer, Susan G ^a   Lee, Carol M ^c   Schertzer, Robert M ^a   Abrams, Gary W ^d   Johnson, Mark W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Andersen Eye Center   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPIVEFRINE; LATANOPROST; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; APHAKIA; ARTICLE; BLOOD RETINA BARRIER; EYE IRRITATION; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA MACULA CYSTOID EDEMA; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0033503790     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)00528-X     Document Type: Article

References (27)

1. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304.
2. Wand M. Latanoprost and hyperpigmentation of eyelashes. [letter]. Arch Ophthalmol 1997;115:1206-8.
3. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7.
4. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997;124: 683-5.
5. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105:263-8.
6. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126:37-41.
7. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma [letter]. Arch Ophthalmol 1998;116:679-80.
8. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol 1998;116:680-2.
9. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc 1998;69: 122-8.
10. Wardrop DRA, Wishart PK. Latanoprost and cystoid macular oedema in a pseudophake [letter]. Br J Ophthalmol 1998;82: 843-4.
11. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997;41(Suppl 2):S105-10.
12. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41Suppl2 S129-38.
13. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998;105:82-7.
14. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996;103:1916-24.
15. Hoyng PFJ, Rulo AH, Greve EL, et al. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997;41(Suppl 2):S83-8.
16. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998;126:602-4.
17. 2α-1-isopropyl ester. Exp Eye Res 1987;44:217-26.
18. Schoenwald RD, Deshpande GS, Rethwisch DG, Barfknecht CF. Penetration into the anterior chamber via the conjunctival/ scleral pathway. J Ocul Pharmacol Ther 1997;13:41-59.
19. Green K, Bowman K, Luxenberg MN, Friberg TR. Penetration of topical indomethacin into phakic and aphakic rabbit eyes. Arch Ophthalmol 1983;101:284-8.
20. Chen CC, Anderson J, Shackleton M, Attard J. The disposition of bunolol in the rabbit eye. J Ocul Pharmacol 1987;3:149-57.
21. Acheampong AA, Breau A, Shackleton M, et al. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits. J Ocul Pharmacol Ther 1995;11:489-502.
22. Jampol LM, Po SM. Macular edema. In: Ryan SJ, editor in chief. Retina, 2nd ed. St. Louis:Mosby; 1994; v. 2, chap. 61.
23. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysis. Ophthalmology 1998;105:397-405.
24. Kulkarni P, Payne S. Eicosanoids in bovine retinal microcirculation. J Ocul Pharmacol Ther 1997;13:139-49.
25. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992;114:544-53.
26. Gass JDM. Hypotony maculopathy. In: Bellows JG, ed. Contemporary Ophthalmology. Honoring Sir Stewart Duke-Elder. Baltimore: William & Wilkins; 1972:343-66.
27. Duker JS, Schuman JS. Successful surgical treatment of hypotony maculopathy following trabeculectomy with topical mitomycin C. Ophthalmic Surg 1994;25:463-5.